{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [
    [
      "COVID-19",
      "RBD mutations",
      "SARS-CoV-2 vaccine",
      "SARS-CoV-2 variants",
      "antibody specificity",
      "critically ill",
      "immunoassays",
      "serology"
    ]
  ],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "36197765",
  "DateCompleted": {
    "Year": "2022",
    "Month": "10",
    "Day": "07"
  },
  "DateRevised": {
    "Year": "2022",
    "Month": "10",
    "Day": "11"
  },
  "Article": {
    "ArticleDate": [],
    "Language": [
      "eng"
    ],
    "ELocationID": [],
    "Journal": {
      "ISSN": "1550-8080",
      "JournalIssue": {
        "Volume": "52",
        "Issue": "4",
        "PubDate": {
          "Year": "2022",
          "Month": "Jul"
        }
      },
      "Title": "Annals of clinical and laboratory science",
      "ISOAbbreviation": "Ann Clin Lab Sci"
    },
    "ArticleTitle": "Cohort-Specific Serological Recognition of SARS-CoV-2 Variant RBD Antigens.",
    "Pagination": {
      "StartPage": "651",
      "EndPage": "662",
      "MedlinePgn": "651-662"
    },
    "Abstract": {
      "AbstractText": [
        "Estimating the response of different population cohorts to new SARS-CoV-2 variants is important to customize measures of control. Our goal was to evaluate how antibodies from sera of infected and vaccinated people recognize antigens expressed by different SARS-CoV-2 variants.",
        "We compared sera from vaccinated donors and four patient/donor cohorts: Sera from critically ill patients collected 2-7 days and more than 10 days after admission to an intensive care unit, a NIBSC/WHO reference panel of SARS-CoV-2 positive individuals, and ambulatory or hospitalized (but not critically ill) positive donors. Samples were tested with an anti-SARS-CoV-2 ELISA kit coated with SARS-CoV-2 RBD recombinant antigens including mutations present in eleven of the most widespread variants.",
        "Sera from vaccinated individuals exhibited higher antibody binding (<i>P</i><0.001) than sera from infected (but not critically ill) individuals when tested against the wild type (WT) and each of 11 variants' receptor binding domain (RBD). Antibodies' binding to the SARS-CoV-2 antigens of at least 6 variants, including Variants of Concern (VOCs), was reduced in comparison to the WT in vaccinated and non-critically ill convalescence individuals.",
        "Understanding differences between population cohorts in the antibody titers against WT vs variant RBD antigens can help design variant-specific immunoassays for surveillance and evaluation of the epidemiology of new variants."
      ],
      "CopyrightInformation": "\u00a9 2022 by the Association of Clinical Scientists, Inc."
    },
    "AuthorList": [
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Lawson Health Research Institute, Department of Pediatrics, Western University, Department of Clinical Neurological Sciences, Western University, Department of Physiology & Pharmacology, Western University, London, Ontario, Canada."
          }
        ],
        "LastName": "Fraser",
        "ForeName": "Douglas D",
        "Initials": "DD"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Lawson Health Research Institute, London, Ontario, Canada."
          },
          {
            "Identifier": [],
            "Affiliation": "Department of Pediatrics, Western University, London, Ontario, Canada."
          }
        ],
        "LastName": "Miller",
        "ForeName": "Michael R",
        "Initials": "MR"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Lawson Health Research Institute, London, Ontario, Canada."
          },
          {
            "Identifier": [],
            "Affiliation": "Department of Pediatrics, Western University, London, Ontario, Canada."
          }
        ],
        "LastName": "Martin",
        "ForeName": "Claudio M",
        "Initials": "CM"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Lawson Health Research Institute, London, Ontario, Canada."
          },
          {
            "Identifier": [],
            "Affiliation": "Department of Pediatrics, Western University, London, Ontario, Canada."
          }
        ],
        "LastName": "Slessarev",
        "ForeName": "Marat",
        "Initials": "M"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Diagnostics Biochem Canada Inc, London, Ontario, Canada."
          }
        ],
        "LastName": "Hahn",
        "ForeName": "Paul",
        "Initials": "P"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Diagnostics Biochem Canada Inc, London, Ontario, Canada."
          }
        ],
        "LastName": "Higgins",
        "ForeName": "Ian",
        "Initials": "I"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Diagnostics Biochem Canada Inc, London, Ontario, Canada."
          }
        ],
        "LastName": "Melo",
        "ForeName": "Christopher",
        "Initials": "C"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Diagnostics Biochem Canada Inc, London, Ontario, Canada."
          }
        ],
        "LastName": "Pest",
        "ForeName": "Michael A",
        "Initials": "MA"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Diagnostics Biochem Canada Inc, London, Ontario, Canada."
          }
        ],
        "LastName": "Rothery",
        "ForeName": "Nate",
        "Initials": "N"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Diagnostics Biochem Canada Inc, London, Ontario, Canada."
          }
        ],
        "LastName": "Wang",
        "ForeName": "Xiaoqin",
        "Initials": "X"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Diagnostics Biochem Canada Inc, London, Ontario, Canada."
          }
        ],
        "LastName": "Zeidler",
        "ForeName": "Johannes",
        "Initials": "J"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Diagnostics Biochem Canada Inc, London, Ontario, Canada jcruz@dbc-labs.com."
          }
        ],
        "LastName": "Cruz-Aguado",
        "ForeName": "Jorge A",
        "Initials": "JA"
      }
    ],
    "PublicationTypeList": [
      "Journal Article"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "United States",
    "MedlineTA": "Ann Clin Lab Sci",
    "NlmUniqueID": "0410247",
    "ISSNLinking": "0091-7370"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Antibodies, Viral"
    }
  ],
  "SupplMeshList": [
    "SARS-CoV-2 variants"
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [],
      "DescriptorName": "Antibodies, Viral"
    },
    {
      "QualifierName": [
        "diagnosis"
      ],
      "DescriptorName": "COVID-19"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Protein Binding"
    },
    {
      "QualifierName": [
        "genetics"
      ],
      "DescriptorName": "SARS-CoV-2"
    }
  ]
}